Enovis (NYSE:ENOV) Price Target Cut to $39.00 by Analysts at Wells Fargo & Company

Enovis (NYSE:ENOV) had its price objective decreased by Wells Fargo & Company from $40.00 to $39.00 in a research note published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other brokerages have also weighed in on ENOV. BTIG Research lifted their price target on Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Evercore set a $32.00 price objective on Enovis in a report on Monday, July 6th. William Blair started coverage on Enovis in a research note on Friday, April 17th. They set an “outperform” rating for the company. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Enovis Stock Performance

ENOV opened at $26.68 on Friday. The firm has a fifty day moving average price of $24.62 and a 200 day moving average price of $23.97. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The stock has a market cap of $1.54 billion, a P/E ratio of -1.39 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.05.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter last year, the business earned $0.79 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts anticipate that Enovis will post 3.12 earnings per share for the current year.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 4,200 shares of company stock valued at $92,084 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of ENOV. Arax Advisory Partners acquired a new position in shares of Enovis during the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S acquired a new stake in Enovis during the third quarter worth about $64,000. iSAM Funds UK Ltd acquired a new stake in Enovis during the third quarter worth about $80,000. Finally, Brown Brothers Harriman & Co. purchased a new position in Enovis during the third quarter worth about $90,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.